使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good morning. My name is Kim, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Valeant Second Quarter 2017 Earnings Conference Call. (Operator Instructions) Art Shannon, Senior Vice President, you may begin your conference, sir.
早安。我叫 Kim,今天將擔任本次會議的電話會議主持人。此刻,我謹代表主辦方歡迎各位參加 Valeant 2017 年第二季財報電話會議。(接線員指示) 資深副總裁 Art Shannon,先生,您可以開始會議。
Arthur J. Shannon - Senior VP and Head of IR & Communications
Arthur J. Shannon - Senior VP and Head of IR & Communications
Thank you, Kim. Good morning, everyone, and welcome to Valeant Pharmaceuticals Second Quarter 2017 Financial Results Conference Call. Participating on today's call are Chairman and Chief Executive Officer, Joe Papa; and Chief Financial Officer, Paul Herendeen. In addition to this live webcast, a copy of today's slide presentation and a replay of this conference call will be available on our website under the Investor Relations section.
謝謝你,Kim。各位早安,歡迎參加 Valeant Pharmaceuticals 2017 年第二季財務業績電話會議。今天參與會議的有董事長兼執行長 Joe Papa,以及財務長 Paul Herendeen。除本次即時網路直播外,今日簡報投影片的副本以及本次電話會議的重播,將可於我們網站「投資人關係」專區取得。
Before we begin, we would like to remind you that our presentation today contains forward-looking information. We'd also -- we also ask that you take a moment to read the forward-looking statement legend at the beginning of the presentation, as it contains important information.
在開始之前,我們想提醒各位,今天的簡報包含前瞻性資訊。我們也請各位花一點時間閱讀簡報開頭的前瞻性聲明說明,因其包含重要資訊。
This presentation contains non-GAAP financial measures. For more information about these measures, please refer to Slide 2 of the presentation. Non-GAAP reconciliations can be found in the appendix to the presentation posted on our website.
本簡報包含非 GAAP 財務衡量指標。關於這些衡量指標的更多資訊,請參閱簡報第 2 頁。非 GAAP 調節表可於我們網站所發布之簡報附錄中查閱。
Finally, the financial guidance in this presentation is effective as of today only. It is our policy to generally not update guidance until the following quarter and not to update or affirm guidance other than through broadly disseminated public disclosure.
最後,本簡報中的財務指引僅以今日為準。我們的政策通常是在下一季之前不更新指引,且除透過廣泛公開揭露外,不會更新或確認指引。
With that, it is my pleasure to turn the call over to Joe.
接下來,我很高興把電話交給 Joe。
Joseph C. Papa - Chairman & CEO
Joseph C. Papa - Chairman & CEO
Thank you, Art. Many of you on the call know Art Shannon. Art joined us as Senior Vice President, Head of Investor Relations and Communications on June 19. Art and I worked together in the past, and we are very happy to have him as part of the Valeant team. So welcome, Art.
謝謝你,Art。在座許多與會者都認識 Art Shannon。Art 於 6 月 19 日加入我們,擔任資深副總裁、投資人關係與傳播主管。我過去曾與 Art 共事,我們非常高興他成為 Valeant 團隊的一員。所以,歡迎你,Art。
With that, let me start with the topics we'll cover on today's call. First, I'll give you a high-level overview of what we've accomplished since our last earnings call. I'll then turn the call over to our CFO, Paul Herendeen, to review our Q2 financial results in detail. He will also cover our updated 2017 financial guidance. Then I'll run through some of the highlights in our business units and talk about the new product pipelines before opening the call for some questions.
接著,讓我先說明今天電話會議將涵蓋的主題。首先,我會高層次概述自上次財報電話會議以來我們所完成的事項。接著我會把電話交給我們的財務長 Paul Herendeen,請他詳細回顧第二季財務結果。他也會說明我們更新後的 2017 年財務指引。然後我會快速帶過各事業單位的一些重點,並談談新產品研發管線,之後開放提問。
Starting with Slide 5. This is how we are thinking about the progress we are making towards a turnaround and transformation of our business. We have a journey ahead of us, to be clear. As I've said before, it's going to be a multiyear process to transform this company, but I am very pleased with the progress our team has made so far.
先從第 5 頁投影片開始。這是我們對於朝向業務扭轉與轉型所取得進展的思考方式。坦白說,我們前方仍有一段路要走。如我先前所說,轉型這家公司將是一個跨多年的過程,但我對團隊迄今所取得的進展感到非常滿意。
We completed the stabilization phase in year 1, and we are now on the early part of a 2-year turnaround phase, where our focus is on strengthening our balance sheet, maintaining leadership positions in specialty-driven markets and those markets with above-average growth rates and allocating resources efficiently.
我們在第 1 年完成了穩定化階段,現在正處於為期 2 年的扭轉階段初期;我們的重點是強化資產負債表、維持在以專科驅動市場以及成長率高於平均的市場中的領導地位,並有效率地配置資源。
Now over to Slide 6. Let's run through some of the positive developments since our last earnings call. First, in terms of execution, we continue to deliver on our commitments. Our 2 largest businesses are doing great and are now showing solid organic growth of 8% on a combined basis due to investments we've made.
接著看第 6 頁投影片。我們來回顧自上次財報電話會議以來的一些正面進展。首先,在執行面,我們持續兌現承諾。我們最大的兩項業務表現非常出色,受惠於我們所做的投資,合計已展現 8% 的穩健有機成長。
Our largest segment, Bausch + Lomb/International, which represents 56% of our revenues in the quarter, delivered another quarter of solid growth, driven by increased volumes. The business grew about 6% organically in the second quarter, led by strong organic revenue growth of 9% in China.
我們最大的部門 Bausch + Lomb/International,本季占營收 56%,在出貨量增加的帶動下,再次交出穩健成長的一季。該業務第二季有機成長約 6%,其中以中國 9% 的強勁有機營收成長領先。
Salix, the largest part of the Branded Rx segment, generated organic revenue growth of 16%, largely due to better execution and the investment we made in a new Primary Care sales team. This resulted in XIFAXAN revenues up 16% versus last year.
Salix(品牌處方藥部門中最大的一部分)有機營收成長 16%,主要來自更佳的執行力,以及我們對新成立的基層醫療(Primary Care)銷售團隊所做的投資。因此,XIFAXAN 營收較去年成長 16%。
Our adjusted EBITDA of $951 million was up by approximately 10% versus Q1 2017. New product launches are moving ahead as planned, and we are projecting that the products launched in 2017 will generate over $100 million of annualized revenue.
我們的調整後 EBITDA 為 9.51 億美元,較 2017 年第一季約成長 10%。新產品上市按計畫推進,我們預估 2017 年上市的產品將帶來超過 1 億美元的年化營收。
SILIQ, the lowest priced injectable biologic for moderate-to-severe plaque psoriasis, was launched at the end of July. In our B + L business, we introduced AQUALOX biweekly contact lenses to the Japanese market, launching the Vitesse and Stellaris Elite surgical eye care systems.
SILIQ 作為治療中重度斑塊型乾癬、價格最低的可注射生物製劑,已於 7 月底上市。在我們的 B + L 業務方面,我們將 AQUALOX 雙週拋隱形眼鏡引進日本市場,並推出 Vitesse 與 Stellaris Elite 眼科手術照護系統。
Our new product pipeline has been very active. We received filing acceptance from the FDA for PLENVU, a novel next-generation bowel preparation for colonoscopies; and Luminesse, a treatment for ocular redness. And our team is very busy preparing for additional Dermatology submissions to the FDA in the second half.
我們的新產品研發管線非常活躍。我們已獲 FDA 受理 PLENVU(用於大腸鏡檢查的新型次世代腸道清潔準備藥物)以及 Luminesse(治療眼部充血)的申請。此外,我們的團隊也正積極準備在下半年向 FDA 提交更多皮膚科產品申請。
Moving now to Slide 7, divestitures and debt reduction, 2 areas which continue to be priorities for our team. A year ago on the quarter 2 2016 earnings call, we announced an ambitious goal to repay $5 billion of debt by February 2018. Delivering on this commitment is very important to us, and we are very pleased to announce that we now expect to exceed our commitment to pay down $5 billion of debt from divestiture proceeds and free cash flow before February 2018.
接著看第 7 頁投影片:資產剝離與減債,這兩個領域仍是我們團隊的優先事項。一年前在 2016 年第二季財報電話會議上,我們宣布一項具企圖心的目標:在 2018 年 2 月前償還 50 億美元債務。履行這項承諾對我們非常重要,我們也很高興宣布,目前我們預期可在 2018 年 2 月前,透過資產處分所得與自由現金流,超額達成償還 50 億美元債務的承諾。
Since the beginning of 2016, we have announced approximately $3.8 billion in total asset sales, including future expected milestone payments, and we have achieved a greater than 10x EBITDA multiple for these asset sales. This includes the sale of Dendreon to Sanpower Group, which closed at the end of June. We used the net proceeds of $811 million to pay down senior secured term loans. And last month, we announced agreements to sell iNova Pharmaceuticals and the Obagi Medical Products business for $930 million and $190 million, respectively.
自 2016 年初以來,我們已宣布約 38 億美元的資產出售總額(包含未來預期的里程碑付款),且這些資產出售的 EBITDA 倍數超過 10 倍。其中包括將 Dendreon 出售給 Sanpower Group,該交易已於 6 月底完成交割。我們將 8.11 億美元的淨收益用於償還優先擔保定期貸款。此外,上個月我們宣布協議,分別以 9.30 億美元與 1.90 億美元出售 iNova Pharmaceuticals 與 Obagi Medical Products 業務。
On July 13, we announced that we would use cash on hand to redeem the remaining $500 million of outstanding senior notes due in 2018. Upon redemption, which will be August 15, we will have reduced total debt by $4.8 billion since the first quarter of 2016, and we will have no significant debt maturities and no mandatory amortization requirements until 2020.
7 月 13 日,我們宣布將以手頭現金贖回 2018 年到期、尚未償還的 5 億美元優先票據。在 8 月 15 日完成贖回後,自 2016 年第一季以來我們將已減少總債務 48 億美元,且在 2020 年之前將沒有重大到期債務,也沒有強制攤還要求。
I'm encouraged by the financial flexibility this affords us going forward.
我對這將為我們未來帶來的財務彈性感到鼓舞。
Turning now to some -- the challenges on Slide 8. Our Dermatology business continue to face strong headwinds, and we have taken several actions this year to address some of these challenges. First, we have stabilized the Derm average selling prices versus last year. Second, we have hired a new Derm leadership team. Third, we have rebranded the business unit as Ortho Dermatologics. Most importantly, we will launch new products in this business unit starting with SILIQ for psoriasis. We believe the changes and investments we are making will help stabilize this business in the second half of the year.
接著談談第 8 頁投影片上的一些——挑戰。我們的皮膚科業務仍持續面臨強勁逆風,我們今年已採取多項行動以因應其中部分挑戰。第一,我們已使皮膚科產品的平均售價相較去年趨於穩定。第二,我們已聘任新的皮膚科領導團隊。第三,我們已將該事業單位重新品牌化為 Ortho Dermatologics。最重要的是,我們將自治療乾癬的 SILIQ 起,在該事業單位推出新產品。我們相信,我們所做的變革與投資將有助於在今年下半年穩定這項業務。
We've also improved inventory management to better meet our customer needs, and we are working to resolve manufacturing quality issues at our Tampa facility.
我們也改善了庫存管理,以更好地滿足客戶需求,並且正努力解決我們坦帕(Tampa)廠的製造品質問題。
Yesterday, we announced that we received a Complete Response Letter from the FDA in connection with Vyzulta. This is obviously disappointing news, and we're going to work with the FDA to resolve this matter as soon as possible. Importantly, the FDA did not identify any efficacy or safety concerns with respect to Vyzulta.
昨天,我們宣布就 Vyzulta 相關事宜收到了 FDA 的「完整回覆函」(Complete Response Letter)。這顯然是令人失望的消息,我們將與 FDA 合作,盡快解決此事。重要的是,FDA 並未就 Vyzulta 指出任何療效或安全性方面的疑慮。
Finally, we've made good progress dealing with some of the legacy legal issues the company is facing. We are achieving great outcomes in resolving and managing litigation and investigations, including some of the following: We settled the Salix securities class action litigation for $210 million. I know several individuals speculated that settling this case would cost significantly more than that. We closed the investigation by the New Jersey Department of Law and Public Safety relating to legacy Philidor matters. We achieved dismissal of the Salix shareholder class actions relating to the merger with Salix. We closed the voluntary request letter from the Federal Trade Commission relating to Paragon. We completed and satisfied all inquiries from the Senate Special Committee on Aging and the House Committee on Oversight and Government Reform relative to pricing. And finally, we obtained dismissals on some of the SHOWER to SHOWER cases. Specifically, with respect to SHOWER to SHOWER lawsuits, we believe that Valeant's potential liability is subject to certain indemnification obligation of J&J owed to Valeant. We have provided J&J with notice that the various lawsuits filed against Valeant relating to SHOWER to SHOWER are subject to indemnification by J&J.
最後,我們在處理公司面臨的一些歷史遺留法律問題方面取得了良好進展。我們在解決與管理訴訟及調查方面取得了很好的成果,包括以下幾項:我們以 2.10 億美元和解 Salix 證券集體訴訟。我知道有些人推測和解此案的成本會遠高於此。我們結束了新澤西州法律與公共安全部(New Jersey Department of Law and Public Safety)就歷史 Philidor 事項所進行的調查。我們成功使與 Salix 併購相關的 Salix 股東集體訴訟獲得駁回。我們結束了聯邦貿易委員會(Federal Trade Commission)就 Paragon 相關事宜所發出的自願提供資料請求函。我們完成並滿足了參議院老齡問題特別委員會(Senate Special Committee on Aging)及眾議院監督與政府改革委員會(House Committee on Oversight and Government Reform)就定價相關的所有詢問。最後,我們在部分 SHOWER to SHOWER 案件中獲得駁回。具體而言,就 SHOWER to SHOWER 訴訟而言,我們認為 Valeant 的潛在責任受限於 J&J 對 Valeant 所負的若干賠償(indemnification)義務。我們已通知 J&J,針對 Valeant 提起、與 SHOWER to SHOWER 相關的各項訴訟,均應由 J&J 提供賠償。
On Slide 9, we presented Q2 revenue and adjusted EBITA for each of our business segments. The key point to take away from this slide is that Bausch + Lomb/International and Salix, which together represent 73% of our revenues this quarter, delivered strong top line and adjusted EBITA performance. That said, our Dermatology business is stabilizing, and we're working hard to get it back on track.
在第 9 張投影片中,我們呈現了第二季各業務部門的營收與調整後 EBITA。這張投影片的重點是:Bausch + Lomb/International 與 Salix 兩個部門合計占本季營收的 73%,其營收(top line)與調整後 EBITA 表現強勁。儘管如此,我們的皮膚科業務正在趨於穩定,我們也正努力讓它回到正軌。
I'll provide more comments on each of the business after Paul reviews our financial results in more detail. Paul, I'll turn it over to you now.
在 Paul 更詳細地回顧我們的財務結果之後,我會再就各項業務提供更多評論。Paul,現在交給你。
Paul S. Herendeen - EVP of Finance & CFO
Paul S. Herendeen - EVP of Finance & CFO
Thanks, Joe. Before I get started, I want to make clear that when we use the phrase organic growth related to revenue, we are adjusting reported revenue growth or decline to reflect the changes in FX rates compared with the relevant period in the prior year, what we call constant currency, and for the impact of divested assets.
謝謝,Joe。在我開始之前,我想先說清楚:當我們在營收相關的語境中使用「有機成長」(organic growth)一詞時,我們會將已報告的營收成長或下滑進行調整,以反映相較於前一年同期匯率變動(我們稱之為固定匯率,constant currency)的影響,以及已處分資產的影響。
Next, the basket of LOE products included on the chart in the appendix to our slides continue to have a meaningful impact on our revenue and pretax profits compared with 2016.
接著,投影片附錄圖表中所列的一籃子 LOE 產品,與 2016 年相比,仍對我們的營收與稅前利潤造成顯著影響。
As a reminder, in a normal situation, we would simply call your attention to the impact of LOEs in our discussion of performance. However, the bolus of LOEs hitting the company in the 2016 and 2017 time frame is quite large and creates a growth drag that we cannot overcome. As such, we've tried to be transparent with our expectations for these products so that you can strip away the impact of the LOE products and see through to the performance of the balance of our business. The decline in the LOE products reduced revenue by some $110 million and pretax profits by roughly $100 million in the quarter compared with Q2 of '16. I'll call out the impact of the LOE products a few times in my remarks. So I want to be clear as to why I'm doing that.
提醒一下,在正常情況下,我們只會在討論業績表現時提示 LOE 的影響。然而,2016 與 2017 年期間公司遭遇的 LOE 集中到期量相當龐大,造成我們無法克服的成長拖累。因此,我們嘗試對這些產品的預期保持透明,讓各位可以剔除 LOE 產品的影響,更清楚看見其餘業務的表現。與 2016 年第二季相比,本季 LOE 產品的下滑使營收減少約 1.10 億美元,稅前利潤約減少 1.00 億美元。我在接下來的說明中會多次提到 LOE 產品的影響。所以我想先說明我為何要這麼做。
Slide 10, financial results. Top-level summary, compared with the prior year quarter, revenue declined 8%. However, 220 basis points of that decline was due to changes in FX rates, and another 280 basis points was due to the divestiture of assets, mainly the skin care assets in the B + L/International segment and Ruconest in Branded Rx.
第 10 張投影片,財務結果。整體摘要:與去年同期相比,營收下滑 8%。不過,其中 220 個基點的下滑來自匯率變動,另有 280 個基點來自資產處分的影響,主要是 B + L/International 部門的護膚資產,以及 Branded Rx 的 Ruconest。
On an organic basis, our business was down approximately 3%. If you further strip out the $110 million decline of the basket of LOE products, revenue from the balance of our business grew roughly 2%. The decline in the basket of the LOE products also impacted our adjusted gross margin in the quarter as the LOE products are among our higher gross margin assets.
以有機基礎計算,我們的業務約下滑 3%。若再進一步剔除那一籃子 LOE 產品 1.10 億美元的下滑,其餘業務的營收約成長 2%。該一籃子 LOE 產品的下滑也影響了本季的調整後毛利率,因為 LOE 產品屬於我們毛利率較高的資產之一。
Adjusted gross margin declined by some 240 basis points, mainly due to mix, and to a lesser extent, the unfavorable impact of movement in foreign exchange rates. Below the gross profit line, I want to point out that the year-over-year decrease in our investment in R&D does not reflect an intention to reduce our investment. It's more the phasing of that investment, removing some projects related to divested businesses and the rebalancing of our R&D projects to better align with our long-term plans.
調整後毛利率下滑約 240 個基點,主要由產品組合(mix)所致,另有較小部分來自匯率變動的不利影響。在毛利以下,我想指出:我們研發(R&D)投資的年對年下降,並不代表我們打算降低投資。這更多是投資時點的安排,包括移除一些與已處分業務相關的專案,以及重新平衡研發專案,使其更符合我們的長期規劃。
Adjusted EBITDA declined 13% on a reported basis. The impact of FX on adjusted EBITDA compared with the prior year quarter was a slight tailwind with the transactional FX gains on intercompany debt more than offsetting the translational FX headwinds. The biggest factors driving the $136 million reduction in adjusted EBITDA were the $100 million impact coming from LOEs and the impact of the divested assets, which reduced profit by some $35 million compared with Q2 of '16. Adjusted EBITDA from the balance of our business was roughly flat versus the prior year quarter.
調整後 EBITDA 以已報告口徑計算下滑 13%。與去年同期相比,匯率對調整後 EBITDA 的影響略為順風:公司間債務的交易性匯兌收益(transactional FX gains)超過了換算性匯兌逆風(translational FX headwinds)。推動調整後 EBITDA 減少 1.36 億美元的最大因素,是 LOE 帶來的 1.00 億美元影響,以及已處分資產的影響;後者使利潤相較於 2016 年第二季減少約 3,500 萬美元。其餘業務的調整後 EBITDA 與去年同期相比大致持平。
Turning to our 3 segments on Slide 11. B + L/International posted a strong quarter with organic revenue growth of roughly 6% compared with Q2 of 2016; 2% of that came from price and 4% from volume. Reported revenues declined roughly 3%, driven by unfavorable movements in FX rates and the impact of -- excuse me, divested assets. Of the roughly 6% organic growth in revenue, about 3/4 came from increased volumes and the balance from realized price increases compared with the prior year quarter.
接著看第 11 張投影片的三大部門。B + L/International 本季表現強勁,與 2016 年第二季相比,有機營收成長約 6%;其中 2% 來自價格、4% 來自銷量。已報告營收約下滑 3%,主要受匯率不利變動以及——抱歉——資產處分的影響所致。在約 6% 的有機營收成長中,約四分之三來自銷量增加,其餘則來自相較去年同期已實現的價格上調。
Our non-B + L/International businesses were the stars of the quarter, up 17% on an organic basis, with notable contributions from our Middle East/Africa cluster, Russia, China and Mexico. The global B + L businesses grew 2% on an organic basis, and within that, Ophtha Rx was up 4%; consumer, up 3%; surgical, up 1%; and Vision Care was down 2%.
我們的非 B + L/International 業務是本季的亮點,有機基礎成長 17%,其中中東/非洲群組、俄羅斯、中國與墨西哥貢獻尤為顯著。全球 B + L 業務有機成長 2%;其中,Ophtha Rx 成長 4%;消費品成長 3%;手術業務成長 1%;而視力保健(Vision Care)下滑 2%。
Within operating expenses in the segment, we continue our efforts to reorganize and streamline the global B + L and International operations. And under Tom Appio's leadership, we're seeing results.
在該部門的營運費用方面,我們持續推動全球 B + L 與 International 營運的重組與精簡。在 Tom Appio 的領導下,我們正看到成效。
SG&A expenses were down $29 million compared with Q2 of 2016. Roughly $8 million of the favorable variance reflected successful and continuing efforts to be more efficient in the deployment of our operating expense dollars. $12 million came from expenses we successfully eliminated following divestitures, and the balance came from changes in FX rates.
SG&A 費用較 2016 年第二季減少 2,900 萬美元。其中約 800 萬美元的有利差異,反映我們在營運費用資金配置上提升效率的成功且持續的努力。1,200 萬美元來自我們在處分後成功刪減的費用,其餘則來自匯率變動。
Adjusted EBITA in the segment was down 2% on a reported basis and up 4% on a constant currency basis, and would have been up even more but for the $17 million reduction of segment profit relative to Q2 of '16 due to the divestiture of the Skin Care and other assets. The impact of the LOES on this segment was negligible. All in all, B + L/International posted solid results in Q2.
該分部的調整後EBITA按報告基礎下降2%,按固定匯率基礎上升4%;若非因出售Skin Care及其他資產,導致相較於2016年第二季該分部利潤減少1,700萬美元,增幅本可更高。LOES對該分部的影響可忽略不計。總體而言,B + L/International於第二季繳出穩健的業績。
Now on to Slide 12 and the Branded Rx segment. The segment was essentially flat on an organic basis compared with Q2 of '16. The divestiture of Ruconest and the late Q2 closing of Dendreon both impacted the reported decline of 3%.
接著看第12頁投影片與Branded Rx分部。與2016年第二季相比,該分部按有機基礎基本持平。出售Ruconest以及Dendreon於第二季末完成交割,均影響了報告口徑下3%的下滑。
Within the segment, our Salix business had a very strong quarter, posting organic growth of 16%. We enjoyed improved net pricing in the Salix business as a result of modest price increases across the GI portfolio as well as favorable gross-to-net items compared with the prior year quarter.
在該分部內,我們的Salix業務本季表現非常強勁,有機成長16%。由於GI產品組合的溫和提價,以及相較去年同期更有利的毛額轉淨額(gross-to-net)項目,我們在Salix業務的淨定價有所改善。
While the improved net pricing is awesome, I just caution that part of that improvement is less durable than the rest. Also encouraging, Salix volume was up over the prior year quarter by some 350 basis points, mainly driven by increased demand from XIFAXAN. We made considerable investments in the new Primary Care sales team, and we're starting to see measurable progress growing XIFAXAN prescriptions for IBS-D.
雖然淨定價改善非常出色,但我提醒一下,其中一部分改善的持久性不如其他部分。同樣令人鼓舞的是,Salix的銷量較去年同期上升約350個基點,主要由XIFAXAN需求增加所帶動。我們對新的基層醫療(Primary Care)銷售團隊進行了相當大的投資,並開始看到在IBS-D適應症上推動XIFAXAN處方量成長的可衡量進展。
In Q2 compared with Q2 last year, total prescriptions for XIFAXAN were up 2% while extended units, which means the total prescriptions multiplied by the pills for Rx, were up 4%. After we lost some momentum with XIFAXAN in late 2016 and into Q1 of '17, it's encouraging to have our most recent results showing a return to growth for this important franchise.
本季與去年第二季相比,XIFAXAN總處方量上升2%,而延伸單位(extended units;即總處方量乘以每張處方的藥片數)上升4%。在2016年末至2017年第一季期間XIFAXAN動能有所減弱之後,近期結果顯示這個重要產品線重回成長,令人振奮。
In addition to XIFAXAN, we posted a solid quarter with APRISO, where Rxs were up 7%; and RELISTOR, where Rxs were up 33% versus the year-ago quarter.
除XIFAXAN外,APRISO也繳出穩健一季,處方量上升7%;RELISTOR處方量較去年同期上升33%。
As Joe mentioned, our Dermatology business continues to be in transition and performed below our expectations in the quarter. Filled prescriptions for our promoted brands in Derm declined in Q2 compared with what was a soft Q1, and the low volumes accounted for almost the entire 31% decline in revenue compared with Q2 of '16. The dynamics of the Dermatology segment have been changing over the last several years with payers more aggressively restricting access to branded products. Layer on top of that, the challenges we faced in converting from a specialty pharmacy-based model in early 2016, and we simply have not been able to deliver to our own or likely to your expectations. We take full responsibility for that.
如Joe所提,我們的皮膚科(Dermatology)業務仍在轉型中,本季表現低於我們的預期。第二季皮膚科主推品牌的已配藥處方(filled prescriptions)較第一季(本就偏弱)進一步下滑;低銷量幾乎解釋了相較2016年第二季營收下滑31%的全部原因。過去幾年皮膚科分部的動態一直在變化,付款方(payers)更積極地限制品牌產品的可及性。再加上我們在2016年初從以專科藥局為基礎的模式轉換所面臨的挑戰,我們確實未能達到我們自身、也很可能未能達到各位的期待。對此我們承擔全部責任。
What we've done so far was we put in place the right team, we rightsized the operating expense structure for the business, and we've invested in improved sales support systems and market access. What we need to do from here forward is demonstrate that we can get Derm back to a growth trajectory through improved execution against our existing product portfolio and the successful launch of new products.
到目前為止,我們已建立合適的團隊,調整(縮編)該業務的營運費用結構,並投資於更完善的銷售支援系統與市場准入。接下來我們需要做的是,透過對既有產品組合更佳的執行,以及成功推出新產品,證明我們能讓皮膚科業務回到成長軌道。
There are some encouraging signs in Derm. Realized net selling prices seem to have stabilized, and the most recent prescription data trends suggest that we are regaining traction with our promoted brands.
皮膚科業務也出現一些令人鼓舞的跡象。已實現的淨銷售價格似乎已趨於穩定,而最新的處方數據趨勢顯示,我們正重新獲得主推品牌的動能。
Adjusted EBITA in the Branded Rx segment decreased 7% as total operating expenses, including R&D, rose 1% while unadjusted revenues declined 3% and gross margin declined roughly 100 basis points.
Branded Rx分部的調整後EBITA下降7%,原因是總營運費用(含研發)上升1%,而未調整營收下降3%,毛利率約下降100個基點。
I want to point out that within the Branded Rx segment, we have rebalanced our selling and A&P expenses with reductions in the Dermatology business more than offset by increased investments in the Salix business. The drop in Dermatology sales was the driver of the decline in adjusted EBITA relative to Q2 of 2016.
我想指出,在Branded Rx分部內,我們已重新平衡銷售與廣告促銷(A&P)費用:皮膚科業務的費用削減,已被對Salix業務增加的投資所抵銷並有餘。皮膚科銷售下滑,是相較2016年第二季調整後EBITA下降的主要驅動因素。
Turning to Slide 13 and the Diversified segment. Total revenue for the segment was down 27%, both reported and on an organic basis, with more than 2/3 of that decline tied to the LOE products shown on the slide in the appendix to our slide deck.
接著看第13頁投影片與Diversified分部。該分部總營收按報告口徑及有機基礎均下降27%,其中超過三分之二的降幅與LOE產品有關,這些產品列示於我們投影片附錄中的圖表。
Within the Diversified segment, there are some products and entities, for example the U.S. portion of Solta, that have the ability to grow with our more durable assets. However, our objective in the Diversified segment is to maximize the cash flows associated with the assets in this group with the understanding that the revenue of the segment as a whole is expected to decline over time.
在Diversified分部內,有些產品與實體(例如Solta在美國的部分)具備與我們較具持久性的資產一同成長的能力。然而,我們在Diversified分部的目標,是在理解該分部整體營收預期將隨時間下滑的前提下,最大化此組資產所帶來的現金流。
Turning to Slide 14 and our balance sheet and liquidity. You see that we ended the quarter with more than $2 billion of cash and cash equivalents on hand. After that date, we did use $811 million of that cash to repay senior secured term debt, and we committed another $500 million to call and redeem the remaining $500 million of 6.75% senior notes due in 2018. Which leads to Slide 15, that shows our long-term debt maturity profile pro forma as of August 15.
接著看第14頁投影片,我們的資產負債表與流動性。可以看到,我們在季末持有超過20億美元的現金及約當現金。在該日期之後,我們使用其中8.11億美元現金償還優先擔保定期貸款(senior secured term debt),並另行承諾5億美元以通知贖回並償還剩餘5億美元、2018年到期的6.75%優先票據。因此來到第15頁投影片,顯示截至8月15日按備考(pro forma)基礎計算的長期債務到期結構。
After taking into consideration the $811 million debt repayment from the Dendreon proceeds and the $500 million redemption of bonds, we will have no debt maturities and no mandatory amortization until 2020. The closing of the sales of iNova and Obagi, expected in the second half of 2017, will enable us to address additional mandatory amortization of our term loans in 2020 and beyond and will reduce our senior secured leverage ratio. Based on our current maturity profile, we have time to develop and execute plans to address our debt stacks in 2020, 2021 and beyond.
在考量以Dendreon處分所得償還的8.11億美元債務,以及5億美元債券贖回後,我們在2020年前將沒有任何到期債務,也沒有任何強制攤還(mandatory amortization)。預計於2017年下半年完成的iNova與Obagi出售交割,將使我們得以處理2020年及之後定期貸款的額外強制攤還,並降低我們的優先擔保槓桿比率。基於目前的到期結構,我們有時間制定並執行計畫,以因應2020年、2021年及之後的債務到期安排。
On to Slide 16, our cash flow summary. Net cash provided by operating activities in the second quarter was $268 million. In the quarter, we paid out $210 million to resolve the Salix securities litigation and received $20 million in insurance proceeds for a net impact on operating cash flow of $190 million.
接著看第16頁投影片,我們的現金流摘要。第二季營運活動提供的淨現金為2.68億美元。本季我們支付2.10億美元以解決Salix證券訴訟,並收到2,000萬美元保險理賠款,對營運現金流的淨影響為1.90億美元。
Adjusted for this amount, our cash flow from operations in the quarter was $458 million. Note that we have received or expect to receive an additional $40 million of insurance proceeds against the Salix settlement in Q3.
若將此金額調整回來,本季我們的營運現金流為4.58億美元。請注意,我們已收到或預期在第三季就Salix和解案再收到額外4,000萬美元的保險理賠款。
On to Slide 17 and the revisions to our 2017 guidance. On this slide, you can see the progression of our 2017 guidance from February to today. Today, we lowered our guidance for revenue for 2017 by $200 million across the range to new guidance in the range of $8.70 billion to $8.90 billion.
接著看第17頁投影片與我們對2017年指引的修訂。在此投影片中,您可以看到我們2017年指引自2月以來至今的演進。今天,我們將2017年營收指引區間整體下調2億美元,新的指引區間為87億至89億美元。
This change is a result of 3 factors: first, it reflects the loss of approximately $170 million of Dendreon revenues following the June 28 closing; second, it reflects a $120 million increase in our 2017 revenue expectations for the LOE assets shown on the chart in the appendix to our slides; and third, it reflects a reduced outlook for revenue for the full year 2017 of roughly $150 million, which is net of the impact of favorable movements in FX rates since the date of our May guidance.
此變動源自三項因素:第一,反映6月28日完成交割後,Dendreon營收約減少1.70億美元;第二,反映我們對投影片附錄圖表所示LOE資產之2017年營收預期上調1.20億美元;第三,反映我們對2017年全年營收展望下調約1.50億美元(已扣除自5月發布指引以來匯率(FX)走勢有利變動的影響)。
The reduced outlook is mainly driven by our revised expectations for our Dermatology business. We continue to expect adjusted EBITDA to be in the range of $3.6 billion to $3.75 billion, even while absorbing the impact of the Dendreon divestiture.
下調展望主要是由於我們對皮膚科業務的預期已作修訂。即使吸收 Dendreon 出售的影響,我們仍預期調整後 EBITDA 將落在 36 億至 37.5 億美元的區間。
This expectation is the result of 4 factors. First, the loss of $65 million of operating profit from the closing of the Dendreon transaction. Second, an increase of approximately $105 million related to our revised profit expectations for the LOE assets. Third, $38 million of additional transactional FX gain on intercompany debt balance that increased our adjusted EBITDA in Q2; and four, a reduction of approximately $78 million to reflect the change in our outlook for our overall business, mainly our Dermatology business, that has reduced our expectations for the full year 2017. There are graphical bridges showing the components of the changes to our revenue and adjusted EBITDA guidance on the next slide.
此一預期是由 4 項因素所致。第一,Dendreon 交易完成導致營業利益減少 6,500 萬美元。第二,與我們對 LOE 資產獲利預期修訂相關,增加約 1.05 億美元。第三,因公司間債務餘額產生額外 3,800 萬美元的交易性外匯收益,使我們在第二季的調整後 EBITDA 增加;第四,為反映我們對整體業務(主要為皮膚科業務)展望的變化而減少約 7,800 萬美元,這已降低我們對 2017 全年的預期。下一張投影片有圖表橋接,展示我們營收與調整後 EBITDA 指引變動的各項構成。
With that, let me turn it back to Joe.
接下來,我把時間交還給 Joe。
Joseph C. Papa - Chairman & CEO
Joseph C. Papa - Chairman & CEO
Thank you, Paul. As I mentioned briefly in my opening remarks, our focus on delivering on our commitments. Over the past 18 months, we have made a number of noncore divestitures that have enabled us to simplify our operating model and reduce our debt.
謝謝你,Paul。如我在開場致詞中簡要提到的,我們專注於兌現我們的承諾。在過去 18 個月,我們已進行多項非核心資產出售,使我們得以簡化營運模式並降低負債。
The chart on Slide 19 has been updated from last quarter to show the progress we've made in closing the previously announced transaction and announcing new divestitures. As you can now see, we have now closed 10 of the 12 asset sales we've announced, and we expect Obagi and iNova to close in the second half of 2017.
第 19 張投影片的圖表已自上季更新,以顯示我們在完成先前已宣布交易以及宣布新出售案方面所取得的進展。如你現在所見,我們已完成所宣布 12 項資產出售中的 10 項,並預期 Obagi 與 iNova 將於 2017 年下半年完成交割。
We were able to execute transactions that delivered attractive returns for our shareholders. In the aggregate, the average multiple received, including expected milestone payments, was greater than 10x EBITDA.
我們得以執行交易,為股東帶來具吸引力的報酬。整體而言,包含預期里程碑款項在內,所取得的平均倍數高於 10 倍 EBITDA。
On Slide 20, second quarter revenues for Bausch + Lomb/International segment were $1.241 billion. The business is growing 6% organically, driven by continued strength in China. China has delivered organic revenue growth of 9% year-over-year, and the Europe and Africa/Middle East were up 11% year-over-year in organic revenue growth. We're also excited about the launch of AQUALOX in Japan. These lenses were developed in-house by our scientists to offer maximum comfort, and they represent the first new innovation in the biweekly contact lens category in 5 years.
在第 20 張投影片,Bausch + Lomb/International(博士倫/國際)事業部第二季營收為 12.41 億美元。在中國持續強勁的帶動下,該業務有機成長 6%。中國的有機營收年增 9%,而歐洲與非洲/中東的有機營收年增 11%。我們也對在日本推出 AQUALOX 感到振奮。這些鏡片由我們的科學家內部研發,旨在提供最大舒適度,並代表雙週拋隱形眼鏡品類 5 年來的首次新創新。
And in terms of new product development, Luminesse is filed with a PDUFA date in December of 2017. We're proud to have developed Vitesse, the first-and-only hypersonic device and the first major vitreous removal innovation in 40 years. We've received FDA clearance in April 2017. The first case was on July 18, 2017.
在新產品開發方面,Luminesse 已送件,PDUFA 日期為 2017 年 12 月。我們很自豪已開發出 Vitesse——首款且唯一的超音速裝置,也是 40 年來玻璃體移除領域的首次重大創新。我們已於 2017 年 4 月取得 FDA 核准。首例手術於 2017 年 7 月 18 日進行。
In addition, the rollout of the Stellaris Elite cataract system has been successful, and we're receiving positive comments from surgeons on the system's performance.
此外,Stellaris Elite 白內障系統的推廣進展順利,我們也收到外科醫師對該系統表現的正面回饋。
Briefly on our surgical business, we are committed to this business, which we view as an important part of an integrated eye care, and we will continue to invest in this business.
簡要談一下我們的手術業務:我們致力於此業務,並將其視為整合式眼科照護的重要一環,我們將持續投資於此業務。
Staying with B + L on Slide 21, we provide an update on our Consumer business. To call out a few highlights. Overall, the global Consumer business continues to perform very well, with the U.S. Vision Care consumption up 2% year-over-year. This is the 22nd consecutive quarter of consumption growth for the U.S. Consumer business. We continue to invest in our Consumer business, and are clear the investments we've made in our brands are delivering results. Biotrue and PreserVision are showing strong growth as a result of recent ad campaigns we've undertaken to support these brands.
延續第 21 張投影片的 B + L(博士倫),我們提供消費者業務的最新進展。點出幾項重點。整體而言,全球消費者業務持續表現優異,美國視力照護(Vision Care)消費量年增 2%。這是美國消費者業務連續第 22 季的消費量成長。我們持續投資於消費者業務,並清楚看到我們在品牌上的投資正在帶來成果。由於我們近期為支持這些品牌所進行的廣告活動,Biotrue 與 PreserVision 皆展現強勁成長。
In terms of revenue, the Biotrue Multipurpose Solution is up 8.4%, and PreserVision is up 12.1% versus last year. This strong performance is a testament to the team's commitment to providing innovative quality Vision Care products that meet the needs of our customers.
就營收而言,Biotrue 多功能護理液成長 8.4%,PreserVision 較去年成長 12.1%。這樣的強勁表現證明團隊致力於提供創新且高品質的視力照護產品,以滿足客戶需求。
Moving now to Slide 22. Salix, which represents 17% of our revenues, has been a standout this quarter, generating $387 million of revenue compared to $302 million last quarter. XIFAXAN in particular made strong progress over the first quarter, driven by strong sales in May and June. New Rx market share was up 400 basis points from March to June, from 73% to 77%, and revenues increased $185 million in quarter 1 to $233 million in quarter 2.
接著看第 22 張投影片。Salix 佔我們營收的 17%,本季表現突出,營收達 3.87 億美元,較上季的 3.02 億美元增加。其中 XIFAXAN 在第一季期間取得強勁進展,主要受 5 月與 6 月銷售強勁帶動。新處方(New Rx)市占率自 3 月至 6 月上升 400 個基點,從 73% 提升至 77%,營收也從第一季的 1.85 億美元增加至第二季的 2.33 億美元。
Drilling down on -- for a moment on XIFAXAN, you can see the strong new Rx share growth among Primary Care targets, which is up 1,200 basis points from 21% to 33%. We attribute this strong performance to the investment we made in a Primary Care sales force.
稍微深入談一下 XIFAXAN:你可以看到在基層醫療(Primary Care)目標客群中的新處方市占率強勁成長,上升 1,200 個基點,從 21% 提升至 33%。我們將此一強勁表現歸因於我們對基層醫療銷售團隊的投資。
Our other sales -- Salix products are also performing very well. RELISTOR prescriptions grew by 33%. APRISO grew by 7% year-over-year, and we are committed to continuing to grow this business. You can see the progress of our products compared to last quarter in the chart in the lower right-hand corner. TRxs for XIFAXAN franchise are up 6%; RELISTOR franchise is up 21%; and UCERIS franchise is up 7%; and APRISO is up 4%.
我們其他 Salix 產品的銷售也表現非常好。RELISTOR 處方量成長 33%。APRISO 年增 7%,我們也承諾將持續推動此業務成長。你可以在右下角圖表中看到我們產品相較上季的進展。XIFAXAN 產品線的 TRxs 上升 6%;RELISTOR 產品線上升 21%;UCERIS 產品線上升 7%;APRISO 上升 4%。
On to Slide 23. As we mentioned earlier, we are committed to working through the challenges facing the Dermatology business and investing in research and development to reinvigorate the Dermatology portfolio. I want to assure you that we are taking steps to improve the performance of the Dermatology business. First, we rightsized the sales force from 250 individuals to 151 sales representatives. Second, we are stabilizing Dermatology average selling prices. Third, we continue to work with our partner, Walgreens, to modify and enhance our agreement.
接著看第 23 張投影片。如我們先前提到的,我們致力於克服皮膚科業務所面臨的挑戰,並投資研發以重振皮膚科產品組合。我想向各位保證,我們正在採取措施改善皮膚科業務的表現。第一,我們將銷售團隊規模從 250 人調整至 151 名業務代表。第二,我們正在穩定皮膚科產品的平均售價。第三,我們持續與合作夥伴 Walgreens 合作,修改並強化我們的協議。
Additionally, the new management team is taking further steps to optimize the business, which we recently rebranded as Ortho Dermatologics with a mission to be the most trusted Dermatology company in the United States. We also expect SILIQ to be a new growth driver for the business. SILIQ was launched on July 27. I spent some time with key opinion leaders at the product launch event last week, and I was strongly encouraged by their enthusiasm for SILIQ's unique method of action and strong efficacy. We are leveraging these key opinion leaders to educate and activate patients who can benefit from the pharmacologic properties of an IL-17 blocker.
此外,新的管理團隊正採取進一步措施以優化業務;我們近期將其重新品牌化為 Ortho Dermatologics,使命是成為美國最值得信賴的皮膚科公司。我們也預期 SILIQ 將成為該業務新的成長動能。SILIQ 已於 7 月 27 日上市。上週我在產品上市活動中與關鍵意見領袖交流了一段時間,他們對 SILIQ 獨特的作用機轉與強勁療效所展現的熱忱,讓我深受鼓舞。我們正運用這些關鍵意見領袖,教育並促動可受益於 IL-17 阻斷劑藥理特性的患者。
At the same time, we are preparing to submit the FDA filing for IDP-118, which we believe has the potential to be a very promising topical product for the treatment of psoriasis.
同時,我們正準備提交 IDP-118 的 FDA 申請文件;我們相信其有潛力成為治療乾癬相當具前景的外用產品。
Moving on to Slide 24. The products launched in the last 12 months, such as SILIQ, AQUALOX, Vitesse, are expected to generate more than $100 million of annualized revenue in 2017, and importantly, drive sustainable long-term growth.
接著看第24頁投影片。過去12個月推出的產品,例如SILIQ、AQUALOX、Vitesse,預期在2017年可帶來超過1億美元的年化營收;更重要的是,將推動可持續的長期成長。
On the left side of Slide 25, you can see that we continue to refresh our late-stage pipeline, with approximately 80% of the programs targeted to launch in the 2017 to 2019 timeframe. On the right, we've listed the innovations we are working on, including late-stage programs, submissions and new product launches.
在第25頁投影片左側,您可以看到我們持續更新後期研發管線,約80%的專案目標在2017年至2019年的時間範圍內上市。右側則列出我們正在推進的創新項目,包括後期專案、申報以及新產品上市。
For example, we recently completed a Phase II trial with [SAN 300]. We learned that SAN 300 , a biologic for autoimmune disease, is very well tolerated with no significant toxicity even at the highest dosing levels. Biomarkers did show evidence of related anti-inflammatory activity, but we will need to do some additional work before we make any decisions on next steps. The initiatives in this list have either been completed or are on track to be completed in the expected time frame.
例如,我們最近完成了[SAN 300]的第二期臨床試驗。我們了解到,SAN 300作為一款用於自體免疫疾病的生物製劑,即使在最高劑量水準下也具有良好耐受性,未見顯著毒性。生物標記確實顯示出相關的抗發炎活性證據,但在我們對下一步做出任何決定之前,仍需要進一步工作。此清單中的各項計畫要麼已完成,要麼正按預期時程推進並將在預期時間內完成。
Let me call out just a few of the programs we're excited about. First, IDP-126, an acne triple combination program. Second, we have IDP-118, a topical psoriasis product that we anticipate to submit later this year. Finally, I'll call out some of the new launches: Stellaris Elite, which is a Vision Enhancement System; Ultra for astigmatism contact lens; Vitesse, of course; and SILIQ for the treatment of moderate-to-severe plaque psoriasis. So we have a number of new opportunities here. We believe these products will be our growth drivers for the future, and importantly, our investments in R&D will enable us to deliver on our mission of improving peoples' lives.
我想特別點出幾個我們感到振奮的專案。第一,IDP-126,一項治療痤瘡的三合一複方專案。第二,IDP-118,一款外用乾癬產品,我們預計將於今年稍晚提交申報。最後,我也要提到一些新上市產品:Stellaris Elite(視覺增強系統);用於散光的Ultra隱形眼鏡;當然還有Vitesse;以及用於治療中度至重度斑塊型乾癬的SILIQ。因此,我們在這裡有多項新的機會。我們相信這些產品將成為未來的成長驅動力;更重要的是,我們在研發上的投資將使我們能夠實現改善人們生活的使命。
To conclude, on Slide #26, our second quarter results demonstrate that we are delivering on our commitments and are making tangible progress towards a turnaround.
最後總結,在第26頁投影片,我們第二季的結果顯示,我們正在兌現承諾,並在扭轉局勢方面取得具體進展。
A few examples just to highlight. Adjusted EBITDA was up approximately 10% quarter-over-quarter. Debt reduction remains a focus, and we now expect to exceed our commitment to pay down $5 billion of debt before February 2018. Our B + L business is growing organically, 6%, and we are seeing strong performance in Asia, particularly in China, where the brand is synonymous with eye care; and of course, in Europe and Middle East. In our Salix business, our investment in Primary Care sales force has resulted in organic revenue growth of 16%, and the XIFAXAN trends are very promising. And the investments we are making in our pipeline have resulted in launches of SILIQ, AQUALOX and a strong late-stage pipeline of innovative and promising products that will be the foundation for our future growth. We remain laser-focused on our commitments, and these results confirm that the steps we are taking are moving us in the right direction.
舉幾個例子來重點說明。調整後EBITDA較上一季約成長10%。降債仍是重點,我們目前預期將超越在2018年2月前償還50億美元債務的承諾。我們的B + L業務有機成長6%,且在亞洲表現強勁,尤其是在中國,該品牌幾乎等同於眼部護理;當然在歐洲與中東也表現良好。在Salix業務方面,我們對基層醫療(Primary Care)銷售團隊的投資帶來了16%的有機營收成長,而XIFAXAN的趨勢非常令人鼓舞。此外,我們對研發管線的投資促成了SILIQ、AQUALOX的上市,以及一條強勁的後期創新且前景可期的產品管線,將成為未來成長的基礎。我們仍然高度聚焦於各項承諾,而這些結果也證實我們採取的措施正把我們帶往正確方向。
With that, operator, let's open up the line for questions.
接下來,接線員,請開放電話線讓大家提問。
Operator
Operator
(Operator Instructions) And your first question comes from the line of David Risinger with Morgan Stanley.
(接線員指示) 您的第一個問題來自Morgan Stanley的David Risinger。
Joseph C. Papa - Chairman & CEO
Joseph C. Papa - Chairman & CEO
David?
David?
Paul S. Herendeen - EVP of Finance & CFO
Paul S. Herendeen - EVP of Finance & CFO
David, are you there?
David,你在線上嗎?
Operator
Operator
Your next question comes from the line of Umer Raffat with Evercore.
您的下一個問題來自Evercore的Umer Raffat。
Umer Raffat - Senior MD and Fundamental Research Analyst
Umer Raffat - Senior MD and Fundamental Research Analyst
Perhaps first, Paul, Joe, how are you thinking about the $5 billion maturities in 2020? There's a lot of investor feedback and questions around a possible use of some sort of combination of a convert, divestitures and/or even perhaps an equity offering. So I just wanted to get color from you on that. Perhaps one for Scott. Scott, the SILIQ is now the lowest priced biologic on a WAC basis. Is it also so on a net basis? And if so, what type of feedback are you hearing from docs on how the REMS component is or isn't offsetting the fact that it actually is a cheaper alternative? And finally, just wanted to get a bit more specific feedback on exactly what remains unremediated on the Florida Bausch facility for latanoprostene.
首先,Paul、Joe,你們如何看待2020年到期的50億美元債務?投資人對於可能採用某種可轉換工具、資產剝離,和/或甚至可能進行股權發行的組合,有很多回饋與疑問。所以我想請你們就此提供一些看法。另外一題可能給Scott。Scott,SILIQ目前按WAC口徑計算是價格最低的生物製劑。按淨價口徑也是如此嗎?如果是,你從醫師那邊聽到的回饋是什麼?REMS的要求是否、或不是否在某種程度上抵消了它其實是更便宜替代方案這一點?最後,我想更具體了解一下,佛羅里達Bausch廠在latanoprostene方面究竟還有哪些事項尚未完成整改。
Joseph C. Papa - Chairman & CEO
Joseph C. Papa - Chairman & CEO
All right. Let me -- Paul, you take the first one on the debt, and then I'll take the SILIQ and then the Tampa.
好的。我來——Paul,你先回答第一個關於債務的問題,然後我再回答SILIQ以及Tampa的部分。
Paul S. Herendeen - EVP of Finance & CFO
Paul S. Herendeen - EVP of Finance & CFO
Sure. Umer, as I said in my prepared remarks, I think the good news is that we have a bit of runway here to deal with the maturities that are coming up in 2020 and then into 2021. Our intention is to deal with those debt stacks through a combination of cash flow generated from our business. Our goal is to generate the maximum cash flow we can and deploy it to reduce our indebtedness. Second would be to use, as available, senior secured leverage to address those unsecured bonds that are due in 2020 and 2021. And third would be, to the extent that we continue to sell assets, that would obviously reduce our refinancing requirements for those debt stacks. And then last, and as I said in a number of different conferences over the course of last, call it, 3 to 4 months, we always have to have on the table the prospect of raising equity or reissuing equity-linked-type securities to deal with that debt stack. Obviously, it is our preference to use cash flow, senior secured leverage and proceeds from the sale of noncore assets as a means of reducing that debt stack in 2020.
好的。Umer,正如我在事先準備的發言中提到的,好消息是,我們在處理2020年以及延伸到2021年的到期債務方面,還有一些時間緩衝。我們的意圖是透過公司業務所產生的現金流組合來處理這些債務梯隊。我們的目標是盡可能產生最大現金流,並將其用於降低負債。第二,則是在可行的情況下,運用優先擔保槓桿(senior secured leverage)來處理2020年與2021年到期的無擔保債券。第三,在我們持續出售資產的程度上,這顯然會降低我們對這些債務梯隊的再融資需求。最後,正如我在過去大約3到4個月的多場會議中所說,我們也必須把籌集股權資金或重新發行股權連結型證券以處理該債務梯隊的可能性放在桌面上。顯然,我們的偏好是以現金流、優先擔保槓桿以及出售非核心資產的所得,作為降低2020年債務梯隊的方式。
Joseph C. Papa - Chairman & CEO
Joseph C. Papa - Chairman & CEO
Next part of the question was relative to SILIQ and the WAC and net. Obviously, we don't have all of the net charges. We just do know that, number one, we priced SILIQ to be the most affordable biologic for the treatment of psoriasis. As we look at what we are doing with the different physicians that we're talking to boot -- about, we are very encouraged by the response we're getting. We're still working through some of the managed care contracts and agreements, but the physician response has been very favorable to the product, predominantly because of the efficacy profile and our status as the only IL-17 blocker. I think we've continued to look to generate more data, not only the initial, the fast uptake of the SILIQ product relative to patient response, but also the opportunity to show the durability of the patient response, and we think that's what's going to be the primary reason why people will use it over time. But we're continuing to work to get additional access with managed care on the agreements. Importantly, we think this is going to be an important product for patients who have psoriasis because of the significant efficacy associated with SILIQ, and we're working through the REMS program, which we -- physicians -- have already signed up physicians for the program as we sit here today.
問題的下一部分是關於SILIQ的WAC與淨價。顯然,我們目前還沒有所有的淨額扣減(net charges)資料。但我們確實知道,第一,我們對SILIQ的定價是要讓它成為治療乾癬最可負擔的生物製劑。就我們與不同醫師的溝通來看,我們對目前獲得的回應感到非常鼓舞。我們仍在推進部分管理式醫療(managed care)的合約與協議,但醫師對產品的反應非常正面,主要是因為其療效特徵,以及我們作為唯一IL-17阻斷劑的定位。我認為我們也持續努力產出更多數據,不僅是SILIQ產品在病患反應上的初期快速起效,也包括展示病患反應的持久性;我們認為這將是人們長期使用它的主要原因。不過,我們仍在持續努力,透過協議在管理式醫療端取得更多可及性。重要的是,我們認為由於SILIQ具備顯著療效,這將是乾癬病患的一項重要產品;而我們也正在推進REMS計畫——截至目前,我們已為該計畫完成醫師的註冊。
On -- the last part of your question was about Tampa. We are working through that. We obviously got a letter from the FDA yesterday afternoon. It is disappointing, as I mentioned in my comments. We do not believe there's any issues of safety or efficacy with Vyzulta. We believe it is specifically related to our Tampa facility. We had an inspection of our Tampa facility. We have responded to the observations from the FDA on that facility, and we've sent them additional response just recently to the FDA. Yesterday was our first feedback from the FDA, and we're going to obviously meet with the FDA and talk to them about the progress that we've made in resolving their questions. But I probably can't comment any further about the specifics of it until we have a firsthand conversation -- another conversation with the FDA. But importantly, we've brought in some new capabilities in our quality team. We've hired a new individual from -- previously with Lachman. We've got a new head for the quality site in our Tampa facility that we hired from Elcon, and we've got some additional medical device experience that we've rehired into our Bausch + Lomb business. So we're taking the steps we think are required to remediate this program.
關於——你問題的最後一部分是關於坦帕。我們正在處理這件事。我們昨天下午顯然收到了 FDA 的一封信。正如我在評論中提到的,這令人失望。我們不認為 Vyzulta 在安全性或有效性方面有任何問題。我們認為這具體與我們的坦帕工廠有關。我們的坦帕工廠曾接受檢查。我們已就 FDA 對該工廠提出的觀察事項作出回覆,並且最近又向 FDA 提交了額外的回覆。昨天是我們首次收到 FDA 的回饋,我們顯然會與 FDA 會面並與他們討論我們在解決其疑問方面所取得的進展。但在我們與 FDA 進行第一手的對話——再次對話——之前,我可能無法就其具體細節再作更多評論。但重要的是,我們已在品質團隊引入了一些新的能力。我們聘請了一位新的人員——此前任職於 Lachman。我們也為坦帕工廠聘請了一位新的品質現場負責人,該人員來自 Elcon;此外,我們也在 Bausch + Lomb 業務中重新聘回了一些具備額外醫療器材經驗的人才。因此,我們正在採取我們認為為補救此計畫所需的步驟。
Operator
Operator
Your next question comes from the line of Gregg Gilbert with Deutsche Bank.
下一個問題來自德意志銀行(Deutsche Bank)的 Gregg Gilbert。
Gregory B. Gilbert - MD and Senior Analyst
Gregory B. Gilbert - MD and Senior Analyst
I have a few here. First, can you speak to non-Bausch + Lomb/International and whether that's core or noncore longer term to Valeant? Paul, on Salix, can you talk a little more about what is temporary about the price effect that helped Salix and quantify the gross-to-net benefit and comment on whether there were any inventory changes in the quarter?
我這裡有幾個問題。首先,你能談談非 Bausch + Lomb/國際業務,以及從長期來看這對 Valeant 而言是核心還是非核心嗎?Paul,關於 Salix,你能再多談一點是什麼「暫時性」的價格效應幫助了 Salix,並量化一下總額到淨額(gross-to-net)的受益,同時評論本季是否有任何庫存變動嗎?
Joseph C. Papa - Chairman & CEO
Joseph C. Papa - Chairman & CEO
Sure. Starting, Gregg, with the non-Bausch + Lomb/International portion, that is an important part of our business. We like that business. Obviously, you're seeing some very significant growth. The leader we have of that business, Tom Appio, who has just done an outstanding job in getting that team focused and delivering on the results. We're very pleased with the business. We very much run it as part of our international business, including both the Bausch + Lomb as well as the non-Bausch + Lomb sales, but we run it as one business unit in each of the countries. So it is critical to us as we think about the future of how that business -- the critical mass we have in the business and how we run it. So we like it. We think Tom's done a great job with it, and we're going to continue to have it as part of our business. I think, Paul, you had the next question on the portion of the Salix price increase.
當然。Gregg,先從非 Bausch + Lomb/國際這一部分開始,這是我們業務中很重要的一部分。我們喜歡這項業務。顯然,你看到了一些非常顯著的成長。我們該業務的負責人 Tom Appio,在讓團隊聚焦並交付成果方面做得非常出色。我們對這項業務非常滿意。我們確實把它作為國際業務的一部分來運營,涵蓋 Bausch + Lomb 以及非 Bausch + Lomb 的銷售,但在每個國家我們都把它作為一個業務單元來運作。因此,當我們思考未來時,這對我們至關重要——包括我們在該業務中的規模臨界點,以及我們如何運營它。所以我們喜歡它。我們認為 Tom 在這方面做得很好,我們將繼續把它作為我們業務的一部分。我想,Paul,你有下一個關於 Salix 漲價部分的問題。
Paul S. Herendeen - EVP of Finance & CFO
Paul S. Herendeen - EVP of Finance & CFO
Yes, which I mentioned -- is part of it is less durable, Gregg. And what I'm talking about there is, to the extent that you have net pricing, it's on XIFAXAN, clearly that is sticky and clearly -- or it is sticky and you'd expect that to continue on into Q3 into Q4. To the extent that we get good pricing on products that are -- have a projected decline, that is less sticky, and so it doesn't stick with the company here as we go ahead into Q3 and 4. But there's really good news there. I mean, if you look at Salix, it was very strong growth in Salix, even setting aside some of that price increase that may not continue on as strongly. I mean, we had volume. We had price. Look at XIFAXAN, for example, if you want to look at an impact of pipeline, because overall, the GI space did not have a lot of pipeline change relative to Q2 of 2016. XIFAXAN did a bit. I mentioned in my prepared remarks, people looking at Rx is up 2%. Well, extended units were up 4%. Volume in XIFAXAN -- fundamental volume, up circa 4% plus. We had the benefit of some modest price increases with respect to the brand, and then we did benefit in the XIFAXAN brand within Salix year-over-year from a relative pipeline expansion. Now before anybody gets excited, pipeline is well within a normal range in 2017 in Q2. It's just that in the year-ago quarter, we had a contraction of, I'll get the number close, it was about 0.4 months versus a contraction in the Q2 of '17 of about 0.1 month. That is a net expansion, if you will, in Q2 of about 0.3 months of XIFAXAN. So that helped that 16% increase year-over-year in the quarter.
是的,正如我提到的——其中一部分的持久性較弱,Gregg。我在這裡指的是:在淨定價方面,如果是在 XIFAXAN 上,顯然那是黏著的,而且你會預期它會延續到第三季、第四季。但如果我們在一些——預期會下滑的——產品上取得了良好的定價,那就比較不黏著,因此當我們進入第三季和第四季時,它不會同樣地留在公司這裡。不過這裡其實有很好的消息。我的意思是,如果你看 Salix,即使先不考慮其中一些可能不會那麼強勁延續的漲價因素,Salix 仍然是非常強勁的成長。我們有量。我們有價。以 XIFAXAN 為例,如果你想看管道(pipeline)的影響,因為整體而言,GI 領域相較於 2016 年第二季並沒有太多管道變化。XIFAXAN 有一些。我在事先準備的發言中提到,大家看處方(Rx)成長 2%。但延伸單位(extended units)成長了 4%。XIFAXAN 的量——基本量——約成長 4% 以上。我們也受益於該品牌一些溫和的漲價;此外,在 Salix 之內,XIFAXAN 品牌相較去年同期也受益於相對的管道擴張。在大家太興奮之前,2017 年第二季的管道水準仍完全在正常範圍內。只是去年同期我們出現了收縮,我把數字說得接近一些,大約是 0.4 個月;而 2017 年第二季的收縮約為 0.1 個月。因此,如果你願意這麼說,第二季淨擴張約 0.3 個月的 XIFAXAN。所以這也幫助了本季年增 16% 的成長。
Gregory B. Gilbert - MD and Senior Analyst
Gregory B. Gilbert - MD and Senior Analyst
And the gross-to-net benefit, too, lastly?
另外,最後一點,總額到淨額(gross-to-net)的受益呢?
Paul S. Herendeen - EVP of Finance & CFO
Paul S. Herendeen - EVP of Finance & CFO
Yes, the gross-to-net benefit was quite modest but also should be sticky.
是的,總額到淨額(gross-to-net)的受益相當溫和,但也應該會是黏著的。
Operator
Operator
Your next question comes from the line of Louise Chen with Cantor Fitzgerald.
下一個問題來自 Cantor Fitzgerald 的 Louise Chen。
Louise Alesandra Chen - Senior Research Analyst & MD
Louise Alesandra Chen - Senior Research Analyst & MD
I had 2 here. So first question I had was, we've often gotten the feedback -- or pushback, that even though you've been very aggressive with debt pay-down, that the leverage ratio isn't coming down fast enough. I'm just curious how should we think about that maybe qualitatively in '18 and beyond. And then secondly, just curious, you've done a lot to stabilize this business and turn things around. But what still keeps you up at night? What are some of the key hurdles left that you think are really important to overcome to get the company back to consistent earnings growth?
我有兩個問題。第一個問題是,我們經常收到回饋——或反對意見——即便你們在償還債務方面非常積極,但槓桿比率下降得不夠快。我只是好奇,我們應該如何在 2018 年及之後,從質性角度來看待這件事。第二個問題是,你們已做了很多工作來穩定這項業務並扭轉局面。但仍有哪些事情讓你夜不能寐?你認為還有哪些關鍵障礙必須克服,才能讓公司回到持續的獲利成長?
Paul S. Herendeen - EVP of Finance & CFO
Paul S. Herendeen - EVP of Finance & CFO
Louise, it's Paul. I'll start with the leverage ratio. Obviously, our goal is to reduce that leverage ratio over time. As we said many times in public forums, our company carries more debt than it should based on the assets that we presently manage. The 2 ways that we can address that the most easily are through generation of cash flow and growth of adjusted EBITDA. Those are absolutely the best ways to do it. So as we look forward, a combination of reducing debt from cash flow, as I outlined, to the extent that we see opportunities to sell assets and improve our credit profile and the quantum of debt, we'll go ahead and do that. The best way is for us to grow our adjusted EBITDA.
Louise,我是 Paul。我先從槓桿比率談起。顯然,我們的目標是隨時間降低槓桿比率。正如我們在許多公開場合多次說過的,基於我們目前所管理的資產,我們公司承擔的債務高於應有水準。我們最容易處理這件事的兩種方式,是透過產生現金流以及成長調整後 EBITDA。這絕對是最好的方式。因此,展望未來,結合我所概述的以現金流降低債務;同時,在我們看到出售資產、改善信用狀況與債務規模的機會時,我們也會去做。對我們而言,最好的方式是成長我們的調整後 EBITDA。
Joseph C. Papa - Chairman & CEO
Joseph C. Papa - Chairman & CEO
Yes. And clearly, I think, as we go to the key hurdles that you're talking about. Number one, it's all about the execution of the business. It's taking and finding ways to grow our Bausch + Lomb business, which we did in the quarter, plus 6% organic, as well as growing the Salix business. That's clearly one of the comments that I made in the call, plus 16% organic. We know that the Derm business is not performing up to expectations, and that's the next area we have to focus. But the good news for us, we think, is that 73% of the business, the Bausch + Lomb/International plus the Salix, is performing at a combined basis of about 8% organically. We think that's a real important factor towards the question for the future.
是的。而且很明顯,我認為,當我們談到你所提到的關鍵門檻時。第一,一切都取決於業務的執行力。也就是採取並找出方法來成長我們的 Bausch + Lomb 業務——我們在本季做到了,有機成長 6% 以上——同時也要成長 Salix 業務。這顯然是我在電話會議中提到的重點之一,Salix 有機成長 16% 以上。我們知道皮膚科(Derm)業務的表現未達預期,這是下一個我們必須聚焦的領域。但對我們而言的好消息是,我們認為業務中有 73%——Bausch + Lomb/International 加上 Salix——合計有機成長約 8%。我們認為這是回答未來相關問題的一個非常重要的因素。
On the question that Paul mentioned on the debt, it is an issue. The good news is we brought it down from $32-plus billion to -- it'll be somewhere in the $27 billion after we make these additional payments. So we think that's an important part of what is critical for us for the future, as Paul very appropriately commented on. Final comment is, we need to continue to resolve some of these legacy legal issues. Christina Ackermann and her legal team are just doing an outstanding job, and I think as mentioned today, we cleared up a number of important issues that have been part of our legacy legal issues. We believe we need to continue to work towards resolving those for the future, and that really will be our focus for the next 3 months and next year.
關於 Paul 提到的負債問題,這確實是一個議題。好消息是,我們已經把它從 320 多億美元降到——在我們做完這些額外付款後——大約會落在 270 億美元左右。因此我們認為,正如 Paul 非常恰當地評論的那樣,這是對我們未來至關重要的一部分。最後一點是,我們需要持續解決一些歷史遺留的法律問題。Christina Ackermann 和她的法務團隊做得非常出色,而且我認為如同今天所提到的,我們已經釐清了多項一直屬於我們歷史遺留法律問題的重要事項。我們相信未來仍需持續努力解決這些問題,而這也將是我們接下來 3 個月以及明年的重點。
Operator
Operator
Your next question comes from the line of Chris Schott with JPMorgan.
下一個問題來自 JPMorgan 的 Chris Schott。
Christopher Z. Neyor - Analyst
Christopher Z. Neyor - Analyst
This is Chris on for Chris. First question, can you elaborate on the progress for rightsizing the Dermatology portfolio between your upcoming launches for SILIQ and IDP-118, the sales force realignment and your work to stabilize ASPs. What's the next steps for the Derm business and how do you think about the balance of restructuring the effort -- your restructuring efforts and upcoming launches?
我是 Chris,代替 Chris 提問。第一個問題,能否更詳細說明你們在皮膚科產品組合「規模適配」(rightsizing)方面的進展,包括即將推出的 SILIQ 與 IDP-118、銷售團隊的重新調整,以及你們為穩定 ASP(平均售價)所做的工作。皮膚科業務接下來的步驟是什麼?你們如何看待重整(restructuring)工作與即將上市新品之間的平衡?
And for second question, can you talk through the 2018 pushes and pulls on EBITDA? Just looking to next year, is flat EBITDA a possibility in 2018? And should we think about EBITDA being down with the divestitures and ongoing price [rising] in diversified business?
第二個問題,能否談談 2018 年 EBITDA 的推力與拉力因素?就明年來看,2018 年 EBITDA 持平是否有可能?考量資產剝離(divestitures)以及多元化業務中持續的價格[上升],我們是否應該預期 EBITDA 會下滑?
Joseph C. Papa - Chairman & CEO
Joseph C. Papa - Chairman & CEO
Sure. Let me start with what we're doing on the Derm business. Clearly, the Derm business, as I mentioned in the call, it has a number of market dynamics that are changing. We're seeing some of the products, for example, some -- retinoid has switched to over-the-counter. We've seen some of the changes in managed care access and rebates and the gross-to-net. And appropriately, what we did is we took the decision early in the year to move to the right number of sales reps for our company. That meant we reduced it from 250 approximately to 151 sales reps. That was an important step to rightsize the expenses relative to what we saw in the portfolio.
當然。我先從我們在皮膚科業務上所做的事情談起。很明顯,正如我在電話會議中提到的,皮膚科業務面臨多項正在變化的市場動態。我們看到某些產品,例如部分——維甲酸類(retinoid)已轉為非處方(OTC)。我們也看到在商業保險/管理式醫療(managed care)可及性、回扣(rebates)以及毛到淨(gross-to-net)方面的一些變化。因此,我們在年初做出正確的決策,將銷售代表人數調整到適合公司的規模。也就是把人數從約 250 人減至 151 名銷售代表。這是重要的一步,讓費用規模與我們在產品組合中所看到的情況相匹配。
As we think about the future though, the very clear direction we have is going to be to grow this business as a result of launching new products. These new product launches, starting with SILIQ last month, then moving to IDP-118, which is, we think, a very novel way to treat psoriasis, are going to a very important opportunities for us to grow this business and to grow EBITDA into 2018 and beyond for the Derm business. But I think that's probably the best I can answer relative to where we're going with it. Clearly, the action steps I talked about also talked about stabilizing the average selling price, which we've done, partnering with our Walgreens and trying to continue to amend and enhance that program, looking at a new branding for the Derm business, a new management team in place. I think we've taken the steps that are going to position us for growth for the future, but it's really going to come down to new products, really, is the important comment.
不過展望未來,我們非常明確的方向是:透過推出新產品來成長這項業務。這些新產品上市——從上個月的 SILIQ 開始,接著是 IDP-118,我們認為這是一種非常新穎的乾癬治療方式——將為我們帶來非常重要的機會,以推動這項業務成長,並在 2018 年及之後提升皮膚科業務的 EBITDA。但我想,這大概是我能就我們將如何推進所能給出的最佳回答。很明顯,我提到的行動步驟也包括穩定平均售價——我們已經做到——與 Walgreens 合作並嘗試持續修訂與強化該計畫,為皮膚科業務導入新的品牌定位,並建立新的管理團隊。我認為我們已採取能讓未來成長就位的步驟,但歸根結底,關鍵評論是:真正重要的是新產品。
Paul S. Herendeen - EVP of Finance & CFO
Paul S. Herendeen - EVP of Finance & CFO
Yes, with respect to EBITDA -- adjusted EBITDA for 2018, we're not going to provide guidance for 2018, but I will provide a couple of things to think about. If you're solely looking at growth -- aggregate growth, stating the obvious, things that need to be taken into consideration are the LOES, the timing of those LOEs and the divestitures and the timing of those divestitures. So if you're simply laying down actual results expected for '17 versus '18, you need to take those into consideration and definitionally, the LOES and the divestitures will be a earnings -- excuse me, a growth drag on '18.
是的,關於 2018 年 EBITDA——調整後 EBITDA——我們不會提供 2018 年的指引,但我會提供幾點供你思考。如果你只是在看成長——整體成長——顯而易見,需要納入考量的因素包括 LOEs(專利到期/失去獨占)、這些 LOE 的時間點,以及資產剝離及其時間點。因此,如果你只是把 2017 年的實際結果與 2018 年的預期結果直接對照,你需要把這些因素納入考量;按定義來說,LOEs 與資產剝離將會對 2018 年的獲利——抱歉,是對 2018 年的成長——造成拖累。
Now interesting, with respect to the LOES, our hope would be that the LOES would continue to get pushed out and we'd gain more revenue and therefore cash flow from those LOES in 2017 and then ultimately, they go -- when they go generic, when they lose their exclusivity, it's a growth drag. But we would prefer, as you've seen, that we continue to see increased revenue expectations for that LOE basket. But those, make no mistake, those are going away in 2018. So that you need to keep that in the back of your head.
另外有趣的是,關於 LOEs,我們的希望是 LOEs 能持續往後延,讓我們在 2017 年從這些 LOE 產品組合中獲得更多營收、因此也帶來更多現金流;而最終當它們——當它們轉為學名藥、失去獨占時——就會成為成長的拖累。但如你所見,我們更希望持續看到對該 LOE 組合的營收預期上修。不過,毫無疑問,這些在 2018 年都會消失。所以你需要把這點放在心上。
The important thing is, I think, talking about LOEs and divestiture, is you strip both of those away and look at our underlying business, Joe referenced, I referenced in my comments about the underlying strength of our core businesses. I mean, I used the B + L business -- B + L/International segment as an example. It's growing strongly. The Salix portion of our Branded Rx business is returned to a growth mode. It's our goal to bring -- excuse me, the Dermatology business back to a growth mode. If we do all those things, then the core part of our business for sure would grow in '18 relative to '17.
我認為重要的是,談到 LOEs 與資產剝離時,把這兩者剔除後再看我們的基本面業務;Joe 在提及核心業務的內在強度時有提到,我在評論中也有提到。我的意思是,我以 B + L 業務——B + L/International 分部——作為例子。它正在強勁成長。我們品牌處方藥(Branded Rx)業務中的 Salix 部分已回到成長模式。我們的目標是讓——抱歉——皮膚科業務也回到成長模式。如果我們把這些都做到,那麼我們業務的核心部分在 2018 年相較 2017 年肯定會成長。
Operator
Operator
Your next question comes from the line of David Amsellem with Piper Jaffray.
下一個問題來自 Piper Jaffray 的 David Amsellem。
David A. Amsellem - MD and Senior Research Analyst
David A. Amsellem - MD and Senior Research Analyst
I have just a couple of questions on the GI business. First on XIFAXAN. Can you talk about the mix from growth related to -- was it driven by primarily IBS or HE or both? And how much of it was just benefit from the more restrictive labeling for VIBERZI? Maybe you can talk to those near-term dynamics.
我有幾個關於腸胃(GI)業務的問題。首先是 XIFAXAN。你能談談成長的組合嗎——主要是由 IBS(腸躁症)或 HE(肝性腦病變)所驅動,還是兩者都有?其中有多少只是因為 VIBERZI 標示(labeling)變得更嚴格而帶來的受益?也許你可以談談這些短期動態。
And then just secondly, on a broader GI question. Before Salix was acquired, there was a fair amount of R&D spend on the business. That's obviously fell by the wayside. I guess, the question here is, this: you've talked about R&D in ophthalmics and Dermatology, not hearing a ton about R&D in the GI space. So maybe you could talk about what you're doing to try to rebuild the R&D infrastructure for the GI business and how much of a priority that is.
第二個是更廣泛的 GI 問題。在收購 Salix 之前,該業務在研發(R&D)上有相當多的支出。那顯然已經被擱置了。我想這裡的問題是:你們談了眼科與皮膚科的研發,但在 GI 領域聽到的研發不多。所以也許你可以談談你們正在做什麼來重建 GI 業務的研發基礎設施,以及這有多高的優先順序。
Joseph C. Papa - Chairman & CEO
Joseph C. Papa - Chairman & CEO
Sure. So let's start the first part of your question. Clearly, the IBS has been an important part of the growth, but I do want to be -- you know we've got specific HE programs that are helping the hepatic encephalopathy as well, especially with patient compliance.
好的。那我們先從你問題的第一部分開始。很明顯,IBS 一直是成長的重要部分,但我也想要——你知道,我們也有一些特定的 HE 計畫在協助肝性腦病變,特別是在病人用藥依從性方面。
First, to deal with the IBS question. The IBS-D opportunity for us was one that was very -- we recognized it going back about 6, 8 months ago, and we looked at it and said, we really need to build additional Primary Care capabilities. We put together that Primary Care capability of over 200 -- approximately 250 sales representatives, sales professionals out there. That was important to us to reach the majority of the IBS physicians that prescribe for IBS products. That work together, got that in place on or about February, and that has really driven a majority of the incremental volume that we're seeing, but I don't want -- I want to be clear that having the incremental sales force and growing that, as I mentioned in the call, 1,200 basis points was absolutely one of the important Primary Care efforts.
首先,先處理 IBS 的問題。對我們而言,IBS-D 的機會是——我們大約在 6 到 8 個月前就已經注意到,並且看了之後認為,我們確實需要建立額外的基層醫療(Primary Care)能力。我們建立了超過 200 人——約 250 名的業務代表、銷售專業人員的基層醫療團隊。這對我們很重要,因為要接觸到多數會開立 IBS 相關產品處方的 IBS 醫師。這些工作整合起來,大約在 2 月左右就到位了,而這確實推動了我們目前看到的大部分增量銷量;但我不想——我想說清楚,正如我在電話會議中提到的,增加並擴大這支額外的銷售團隊(我提到的 1,200 個基點)絕對是基層醫療工作中非常重要的一環。
On HE, though, one of the things we've also put together for HE is additional programs to help with compliance when a patient is first diagnosed and discharged from a hospital with HE to make sure that the patients who are discharged get the appropriate product and stay on it from a compliance point of view. So we put together some nurse educator programs, some discharge planning programs to help us with the HE and making sure that the patient gets the maximum benefit for -- of XIFAXAN so that they do not get readmitted to the hospital. So I think it was both of them. But clearly, it was the IBS is driving most of it.
至於 HE,我們也為 HE 建立了額外的計畫,協助病人在首次被診斷、並因 HE 自醫院出院時的用藥依從性,確保出院的病人能拿到適當的產品,並且從依從性的角度持續用藥。因此我們設立了一些護理師衛教計畫、出院規劃計畫,來協助 HE,並確保病人能從 XIFAXAN 獲得最大效益,讓他們不會再度住院。所以我認為兩者都有影響。但很明顯,主要驅動因素還是 IBS。
On the question, we don't view it specifically by (inaudible) or changes in labeling. We view it as really getting our message out on what we could do with XIFAXAN and importantly, educating the physicians, especially Primary Care.
關於這個問題,我們不會特別以(聽不清)或標示變更來看待。我們的看法是,真正把我們能用 XIFAXAN 做到什麼的訊息傳達出去,更重要的是教育醫師,尤其是基層醫療醫師。
On the question of R&D in next-generation and what we're doing there, I don't necessarily agree with your comment. I did talk specifically in the Salix -- about Salix, some of the things we're doing in R&D for Salix. We, number one, have already filed a next-generation product for colonoscopies. That clearly is one example. The second example is that we have a next-generation patient-friendly alternative that will go into clinical trials in the second half of 2017. We think that is another important advance. And we're going to continue to look at additional indications for XIFAXAN, going after some areas, [CIBO] as an example, looking at other places where XIFAXAN can help patients with any of the gastrointestinal opportunity. So we're clearly going to invest behind this. Look for us to make more announcements in the second half relative to what we're going to do with a next-generation XIFAXAN that we think is going to be a more patient-friendly product and important advance for patients.
關於下一代研發以及我們在那方面做什麼的問題,我不一定同意你的評論。我確實在 Salix——關於 Salix——具體談到我們在 Salix 的研發上正在做的一些事情。第一,我們已經就一個用於大腸鏡檢查的下一代產品提出申請。這顯然是一個例子。第二個例子是,我們有一個更符合病人使用、對病人更友善的下一代替代方案,將在 2017 年下半年進入臨床試驗。我們認為這是另一項重要進展。此外,我們也會持續尋找 XIFAXAN 的其他適應症,鎖定一些領域,例如以 [CIBO] 為例,並在其他地方探索 XIFAXAN 如何在任何腸胃道機會中幫助病人。所以我們很明確會在這方面投入。請期待我們在下半年就我們將如何推進下一代 XIFAXAN 發布更多公告;我們認為那將是一個對病人更友善的產品,也是對病人的重要進展。
Operator
Operator
Your next question comes from the line of Gary Nachman with Bank of Montreal.
你的下一個問題來自蒙特婁銀行(Bank of Montreal)的 Gary Nachman。
Unidentified Analyst
Unidentified Analyst
This is Nicole on for Gary. I just wanted to ask a couple of questions. Have you completely fixed the Walgreens partnership? Or are they still more tweaks that need to happen there?
我是 Nicole,代 Gary 提問。我想問幾個問題。你們已經完全修復與 Walgreens 的合作夥伴關係了嗎?還是那邊仍需要做更多調整?
Joseph C. Papa - Chairman & CEO
Joseph C. Papa - Chairman & CEO
Well, I would say that Walgreens is an important partner for us. What we worked, especially in the Dermatology area, a number of projects with Walgreens to improve the patient experience for patients that go in looking for filling a Dermatology prescription. So we, -- but we clearly do think there are additional things that we're working with Walgreens to improve in the program. So I think, in general, what I'd say is, number one, we've fixed some of the issues we had a year ago, which was relative -- we were seeing in relative average selling prices. Number one, that's been fixed. We feel we now are stabilizing our average selling prices for Dermatology. Number two, I do think there are some additional opportunities for us, and we're talking to Walgreens all the time about what are some of the next-generation opportunities for us to partner with Walgreens for the future and looking at how we can modify or enhance the existing agreements. So I think there are still opportunities there that we'll spend more time working with Walgreens for -- in the future.
嗯,我會說 Walgreens 對我們而言是重要的合作夥伴。我們做了不少工作,特別是在皮膚科領域,與 Walgreens 推動多個專案,以改善前往配領皮膚科處方的病人的就醫與取藥體驗。所以我們——但我們也確實認為,還有一些額外事項正在與 Walgreens 一起努力,以改善這個計畫。因此整體而言,我會這樣說:第一,我們已經解決了一年前的一些問題,主要是與——我們當時看到的平均銷售價格相關的問題。第一點,這已經修復了。我們覺得皮膚科的平均銷售價格現在正在趨於穩定。第二,我確實認為我們還有一些額外機會,我們也一直在與 Walgreens 討論,未來有哪些下一代的合作機會,以及我們如何修改或強化現有協議。所以我認為那邊仍有一些機會,我們未來會花更多時間與 Walgreens 一起推進。
Unidentified Analyst
Unidentified Analyst
Okay. And how much of the Dermatology volume is going through Walgreens? And why aren't we seeing more of a benefit with those prescription trends there?
好的。那皮膚科的量有多少是透過 Walgreens 走的?以及為什麼我們沒有在那邊的處方趨勢看到更多的效益?
Joseph C. Papa - Chairman & CEO
Joseph C. Papa - Chairman & CEO
Yes, I don't know we're going to give out the exact percentage of our Dermatology business that goes through Walgreens. I would say, clearly, Walgreens is an important part of the business, to be clear, relative to just as a general comment. But I don't want to suggest that we're going to give out the percentages right now. But I think the important part, when I step back from Walgreens, or step back from your question to say, what's going on with our programs with Walgreens? We think Walgreens is a good partner, and we're working to try to enhance the program for the future, and that's really how we're doing it, but I probably don't want to give out exact line that goes through Walgreens.
是的,我不確定我們會不會公布皮膚科業務透過 Walgreens 的確切百分比。我會說,很明顯 Walgreens 是業務的重要一部分,這點要說清楚,作為一般性的評論。但我不想暗示我們現在會公布百分比。不過我認為重點是,當我從 Walgreens 這個點退一步、或從你的問題退一步來看:我們與 Walgreens 的計畫到底在做什麼?我們認為 Walgreens 是很好的合作夥伴,我們正在努力強化這個計畫以面向未來,這就是我們的做法;但我可能不想提供透過 Walgreens 的確切比例。
Operator
Operator
Your next question comes from the line of Doug Miehm with RBC Capital Markets.
你的下一個問題來自 RBC Capital Markets 的 Doug Miehm。
Douglas Miehm - Analyst
Douglas Miehm - Analyst
Yes. First question just has to do with the foreign exchange component there. I believe it was $38 million that you're showing in the -- Page 18 on the guidance line in terms of the bridge. I'm just wondering if that was the full amount that was impacting Q2 or if there was an amount from Q1 that I'm just overlooking right now.
是的。第一個問題是關於外匯的組成部分。我相信你們在——指引的橋接表中第 18 頁顯示的是 3,800 萬美元。我想確認一下,這是否是影響第二季的全部金額,或是第一季也有一部分我現在忽略了。
And then, the second question just has to do with the changes in contingent consideration/milestones from 2 30 to 2 70, I think it is, and what that relates to, maybe SILIQ. And then finally, why CapEx dropped from $250 million to $175 million?
然後第二個問題是關於或有對價/里程碑從 2.30 變到 2.70(我想是這樣)的變動,以及那是跟什麼有關,可能是 SILIQ。最後,為什麼資本支出(CapEx)從 2.5 億美元降到 1.75 億美元?
Paul S. Herendeen - EVP of Finance & CFO
Paul S. Herendeen - EVP of Finance & CFO
Yes, I'll start with the FX piece. That $38 million that we call out is the one that you can quite easily find in our financial statements. It's the FX gain on intercompany debt balances that is a component of our adjusted EBITDA, and so it's kind of -- that's what was recognized in the quarter. There was also a gain recognized in Q1 -- help me, someone, with the...
好的,我先從外匯(FX)部分開始。我們提到的那 3,800 萬美元,你可以很容易在我們的財務報表中找到。那是公司間債務餘額的外匯收益,是我們調整後 EBITDA 的一個組成部分,所以——那就是本季認列的項目。第一季也認列了一筆收益——有人幫我一下,那個……
Unidentified Company Representative
Unidentified Company Representative
$26 million, I think, or something like that.
我想是 2,600 萬美元之類的。
Paul S. Herendeen - EVP of Finance & CFO
Paul S. Herendeen - EVP of Finance & CFO
$26 million. It was $26 million in Q1, but specifically, the $38 million was what impacted our adjusted EBITDA in Q2. As you're thinking about the impact of FX in its entirety on adjusted EBITDA, I did call out that it has 2 components. One is this -- a transactional gain; and the other are headwinds, basically less favorable FX rates relative to the prior year period. And net-net, that translated into a bit of a tailwind, not an enormous amount in adjusted EBITDA.
2,600 萬美元。第一季是 2,600 萬美元,但具體來說,影響我們第二季調整後 EBITDA 的是這 3,800 萬美元。當你在思考外匯對調整後 EBITDA 的整體影響時,我確實提到它有兩個組成部分。一個是這個——交易性收益;另一個是逆風,基本上是相較於去年同期更不利的匯率。兩者相抵後,對調整後 EBITDA 形成了一點順風,但幅度不算很大。
Joseph C. Papa - Chairman & CEO
Joseph C. Papa - Chairman & CEO
And the final question was on CapEx. CapEx is something, it just depends on when -- how projects progress through the year. It's really, for us, one of the things that we talked about is changing how we've taken approach to globalize our business and globalize our capital expenditures. Dennis Asharin on our team has done a really nice job in putting together a program and activities for how we look at CapEx, and I think we just believe we can be a little bit more efficient with CapEx this year. As for where it goes for the future, we'll talk more about that next year. But this year, we think we can be a little bit more efficient. Obviously, that helps on our return on capital. That's one of the metrics that we put in place for the company in terms of looking at the future and where -- how we can be more efficient for the future.
最後一個問題是關於資本支出(CapEx)。CapEx 這件事,主要取決於——專案在一年當中推進的進度與時點。對我們而言,我們談到的一件事,是改變我們推動業務全球化以及資本支出全球化的方式與做法。我們團隊的 Dennis Asharin 在整合一套計畫與相關活動方面做得非常出色,讓我們能以更系統化的方式來看待 CapEx;我想我們相信今年在 CapEx 上可以更有效率一些。至於未來會如何配置,我們明年會再多談。但就今年而言,我們認為可以更有效率一些。顯然,這有助於提升我們的資本報酬率。這也是我們為公司所設定、用來展望未來並評估——以及我們如何在未來提升效率——的其中一項衡量指標。
Operator
Operator
And your final question comes from the line of Annabel Samimy with Stifel.
您最後一個問題來自 Stifel 的 Annabel Samimy。
Annabel Eva Samimy - MD
Annabel Eva Samimy - MD
So you've talked about some of the volume and access pressure that you're seeing due to reimbursement and changes in the payer landscape in Dermatology. And it looks like in 2018, there's going to be some more, not just for Derm but also for RELISTOR. So maybe you can talk about what you might do to offset some of this and how are some of your other contracts shaping up for 2018? What might we be expecting there? And then, just to go back to the remediation efforts around the B + L plant, I know that you don't really have much detail at this point, but do you have a sense maybe of the timing? Is this a several-month delay? Is it going to be another refiling of the NDA and 6-month review? Is there going to be a technical delay? Do you have any color there you can provide?
您談到因皮膚科領域的給付(reimbursement)以及付款方環境變化,而看到一些量與可近性(access)的壓力。而看起來在 2018 年,這類情況會更多,不僅在皮膚科,RELISTOR 也會如此。所以或許您可以談談,您可能會做些什麼來抵消其中一部分影響?以及您其他一些合約在 2018 年的進展如何?我們可以期待看到什麼?另外,再回到 B + L 工廠的補救(remediation)工作,我知道您目前沒有太多細節,但您是否能大概掌握時程?這會是延遲好幾個月嗎?會需要重新遞交 NDA 並進行 6 個月審查嗎?會有技術性延遲嗎?您能提供一些看法或補充資訊嗎?
Joseph C. Papa - Chairman & CEO
Joseph C. Papa - Chairman & CEO
Sure. Maybe just a couple comments. Number one, in terms of this, the volume and access, I mean, just -- I probably want to correct some -- there's some noise out there in the system. There was at least one report about whether or not some of the changes in the managed care plans occurred this year or last year. To be clear, some of the changes that occurred with CVS and Caremark really occurred in 2016. So they haven't really been a 2017 event. They were rather a 2016 event, and there really is no significant impact on our business relative to volume and access for our product. Having said that, though, let me go to really the heart of your question in terms of where are we going, and I'd say the most important thing that we can do with our Dermatology business is bring out these new products. I think it's always going to be about new products, new innovation, and that's why I think a product like SILIQ, where we have the most efficacious product or at least as it relates to PASI 100 scores, certainly a very efficacious product, that we think that is going to be the reason why people are going to use our products in terms of the efficacy. We did price it, though, to be clear, as the most affordable product in the area of psoriasis -- biologic for psoriasis. So for that reason, we think we'll get the innovation that's going to be important for patients and allow us to work through some of the issues on the REMS program for that specific patient, physician and pharmacist. So we're excited about innovation. I think it's the #1 way we're going to work through that.
好的。我先補充幾點。第一,關於量與可近性,我的意思是——我可能想更正一些——系統裡有一些雜訊。至少有一份報告提到,某些管理式醫療(managed care)計畫的變更究竟是發生在今年還是去年。為了釐清,CVS 與 Caremark 的一些變更其實是在 2016 年發生的。所以它們並不是 2017 年的事件。而是 2016 年的事件;就我們產品而言,對我們業務在量與可近性方面並沒有顯著影響。不過,回到您問題的核心,也就是我們接下來要往哪裡走——我會說,我們在皮膚科業務上能做的最重要的事,就是推出這些新產品。我認為關鍵永遠在於新產品與新創新;這也是為什麼像 SILIQ 這樣的產品——我們擁有最具療效的產品,或至少就 PASI 100 分數而言,確實是非常具療效的產品——我們認為,療效將是人們使用我們產品的原因。同時也要釐清,我們的定價是把它定位為乾癬領域中最可負擔的產品——也就是乾癬的生物製劑中最可負擔者。因此,我們認為我們能帶來對病患很重要的創新,並讓我們得以針對該特定病患、醫師與藥師,在 REMS 計畫的一些議題上逐步推進與解決。所以我們對創新感到振奮。我認為這是我們解決這些問題的第一要務。
Beyond that, it's always going to come down to the next product, the IDP-118, the IDP-126, all the other products that we'll launch and the innovation that those will bring to the marketplace.
除此之外,最終還是會回到下一個產品:IDP-118、IDP-126,以及我們將推出的所有其他產品,還有它們將為市場帶來的創新。
On the question of Tampa, I really can't say very much more than that. We just got the letter yesterday. We're going to obviously be in touch with the FDA. I know there's an outreach to the FDA even as we speak today. So that's really going to be important thing before I make any specific comments on kind of the next steps or timing. I'm really going to, at this point, want to work through that with FDA. I think we feel we've made significant progress at the Tampa site. We're going to continue to talk to the FDA about some of their observations. We've put together a response to their observations already, and we'll see where it goes for the timing for the future, but thank you very much for your questions, everybody.
關於坦帕(Tampa)這個問題,我實在無法再多說什麼。我們昨天才收到那封信。我們當然會與 FDA 保持聯繫。據我所知,就在今天我們也正在與 FDA 接洽。因此,在我對後續步驟或時程做任何具體評論之前,先與 FDA 溝通清楚將是最重要的事。就目前而言,我希望先與 FDA 一起把這件事處理好。我們認為在坦帕廠址已取得顯著進展。我們會持續就他們的一些觀察事項與 FDA 討論。我們也已經針對他們的觀察事項整理好回覆;接下來就看未來時程會如何發展。非常感謝各位的提問。
Let me close there with saying, I thank you for your participation this morning. We clearly are looking at some of what we think are exciting opportunities for the future of Valeant. First and foremost, really looking at our ability to grow the Bausch + Lomb/International business as well as the Salix business. Having 73% of our business showing the growth that we've showed of approximately, on a combined basis; 8% on an organic basis, we think, is a really exciting preview of our future. And importantly, bringing down the debt, giving us some additional flexibility on how we can manage the debt and having 0 maturities and debt payments between now and 2020, we think, is an important milestone. And importantly, some of the progress we're making on legal liabilities, we think, all those total into a company that we can really begin to have some significant success in our turnaround. But it's not going to happen overnight. It takes some time, but we're excited about what we see for the future. Thank you, everyone, for joining us today on the call. Have a great day.
我在此做個結語,感謝各位今天早上的參與。我們清楚看到一些我們認為對 Valeant 未來而言令人振奮的機會。首要之務,是著眼於我們推動 Bausch + Lomb/國際業務以及 Salix 業務成長的能力。我們有 73% 的業務呈現我們所展現的成長——合併口徑約 8% 的有機成長——我們認為這是對未來非常令人振奮的預告。同樣重要的是,降低負債,讓我們在如何管理負債方面擁有更多彈性;而且從現在到 2020 年之間沒有任何到期(maturities)與債務償付,我們認為這是一個重要的里程碑。此外,我們在法律責任方面取得的一些進展也很重要;我們認為,這些因素加總起來,讓公司能夠在轉型(turnaround)上開始取得相當顯著的成功。但這不會一夕之間發生。這需要一些時間,但我們對未來所看到的感到振奮。感謝各位今天加入我們的電話會議。祝各位有美好的一天。
Operator
Operator
Ladies and gentlemen, this concludes today's conference call, you may now disconnect.
各位女士先生,今天的電話會議到此結束,您現在可以掛線。